During a conference call this morning, Horizon Therapeutics Chief Executive Officer Tim Walbery pointed to the depth of Viela’s research and development programs, the company’s understanding of common mechanisms of autoimmunity, and its strong legacy management from MedImmune as net positives for Horizon. During the call, Walbery said Viela is a “strong strategic fit” that will drive long-term and sustainable growth for Horizon.
Viela Bio’s Uplizna Granted FDA Approval As Company’s First Commercial Product
Viela Bio’s Uplizna™ Granted FDA Approval As Company’s First Commercial Product Viela Bio’s Uplizna™ (inebilizumab-cdon), a treatment for adult patients with neuromyelitis optica spectrum disorder (NMOSD), was approved by the [….]
The Top Biotech Companies That are Hiring – June 2020
The Top Biotech Companies That are Hiring – June 2020 June 9, 2020 Despite the uncertainty created by the COVID-19 pandemic, companies across the BioHealth Capital Region (BHCR) continue to [….]
Industry Leaders Outline Best Strategies for Attracting Talent in the BioHealth Capital Region
Industry Leaders Outline Best Strategies for Attracting Talent in the BioHealth Capital Region Recruiting and attracting talent is one of the top priorities and challenges for biotech and life science [….]
Attracting Talent In The BioHealth Capital Region
These are unprecedented times in which we are all experiencing radical changes and uncertainty due to the COVID-19 Pandemic. However, there is still expected to be a strong demand for [….]
BioHealth Capital Region Startups Raised More Than $739M in 2019
BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]
Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO
Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO October 3, 2019 It has been just 20 months since Viela Bio was founded and today Viela Bio CEO [….]
Why Developing Cures for Rare Disease Isn’t So Rare Anymore
Why Developing Cures for Rare Disease Isn’t So Rare Anymore These Six Maryland Biotech Companies Are Seeing Success in Targeting Rare Diseases September 3, 2019 Groundbreaking technology and scientific advancements, [….]
Viela Bio Becomes Latest Biotech Intent on Going Public with $150M Offering
Viela Bio Becomes Latest Biotech Intent on Going Public with $150M Offering AstraZeneca spinout files for IPO on Nasdaq August 29, 2019 Viela Bio, the AstraZeneca spin-off biotech, has captured [….]
Maryland Pavilion to Showcase State’s Thriving Biotech Community at Annual BIO Convention
BIO 2019 Maryland Pavilion